US EditionArtelo Biosciences (NASDAQ:ARTL) Earns “Buy” Rating from D. Boral Capital
Summary by themarketsdaily.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Artelo Biosciences (NASDAQ:ARTL) Earns “Buy” Rating from D. Boral Capital
Artelo Biosciences (NASDAQ:ARTL – Get Free Report)‘s stock had its “buy” rating reissued by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $6.00 price target on the stock. D. Boral Capital’s target price would suggest a potential upside of 468.72% from the stock’s previous […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
